GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Minority Interest

LumiraDx (LumiraDx) Minority Interest : $-0.12 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

LumiraDx's minority interest for the quarter that ended in Jun. 2023 was $-0.12 Mil.


LumiraDx Minority Interest Historical Data

The historical data trend for LumiraDx's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Minority Interest Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Minority Interest
- -0.21 -0.46 -0.27

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.27 -0.27 -0.18 -0.12

LumiraDx Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.

LumiraDx (LumiraDx) Headlines